AdvisorShares Investments LLC has recently announced that it has increased stake in Enveric Biosciences Inc. (NASDAQ:ENVB) by 22.98%. After grabbing 0.14 million shares, the institutional investor is now in possession of 26721.0 shares of the Healthcare Company. The new investment brought the stake of investor firm to 6.88% having worth around $0.26 million. Moreover, Tower Research Capital LLC increased its share by 4312.0 to have a control over 14129.0 shares. And G1 Execution Services LLC raised its holdings to 12481.0 shares by acquiring 12481.0 shares or 0.60% of the stake.
Enveric Biosciences Inc. (ENVB) concluded trading on 05/24/23 at a closing price of $4.81, with 79.53 million shares of worth about $382.55 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 60.33% during that period and on Wednesday the price saw a gain of about 52.70%. Currently the company’s common shares owned by public are about 2.08M shares, out of which, 1.88M shares are available for trading.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
Sponsored
A deeper look into what the analysts at Wall Street are thinking about the price target of this stock provides us with the following: 1 analysts are covering the ENVB stock and their offered price forecasts bring an average price target of $7.00. Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $7.00 and could fall to a lowest price of $7.00. The stock’s current price level is 31.29% above of average price target set by the analysts, while a rise to estimated low would result in gain of 31.29% for the stock. However, touching the estimated high of $7.00 would mean a gain of 31.29% for the stock.
AdvisorShares Psychedelics ETF, Vanguard Extended Market Index Fu, and Fidelity Extended Market Index Fu are the top 3 mutual funds which are holding stakes in Enveric Biosciences Inc. AdvisorShares Psychedelics ETF is currently holding 0.1 million shares of worth totaling $0.18 million. The company recently came buying 0.0 shares which brought its stake up to 4.83% of the company’s outstanding shares. Fidelity Extended Market Index Fu, after buying 2397.0 shares, have now control over 0.12% of the stake in the company. It holds 0.0 shares of worth $4389.0.
Enveric Biosciences Inc. (NASDAQ: ENVB) started trading at $4.07, above $0.92 from concluding price of the previous day. However, the stock later moved at a day high price of 6.9794, or with a gain of 52.70%. Stock saw a price change of 216.45% in past 5 days and over the past one month there was a price change of 198.76%. Year-to-date (YTD), ENVB shares are showing a performance of 131.25% which decreased to -56.23% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.30 but also hit the highest price of $18.50 during that period. The average intraday trading volume for Enveric Biosciences Inc. shares is 2.24 million. The stock is currently trading 134.00% above its 20-day simple moving average (SMA20), while that difference is up 168.29% for SMA50 and it goes to 52.34% higher than SMA200.
AdvisorShares Investments LLC acquired 0.14 million shares of Enveric Biosciences Inc. having value of about $0.26 million. Data submitted at the U.S SEC by AdvisorShares Investments LLC revealed that the firm now holds 26721.0 shares in the company valued at close to $128528.01, or have control over 22.98% stake in the company. Enveric Biosciences Inc. (NASDAQ: ENVB) currently have 2.08M outstanding shares and institutions hold larger chunk of about 7.20% of that. Holding of mutual funds in the company is about 5.68% while other institutional holders and individual stake holders have control over 8.15% and 5.38% of the stake respectively.
The stock has a current market capitalization of $10.20M and its 3Y-monthly beta is at 1.34. It has posted earnings per share of -$13.74 in the same period. It has Quick Ratio of 3.30 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ENVB, volatility over the week remained 58.83% while standing at 22.46% over the month.
Analysts are in expectations that Enveric Biosciences Inc. (ENVB) stock would likely to be making an EPS of $0 in the current quarter, while forecast for next quarter EPS is $0 and it is $0 for next year. For the current quarter EPS, analysts have given the company a lowest target $0 which is $0 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$89 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 87.50%.
Analysts at 1 brokerage firms have issued recommendations for the Enveric Biosciences Inc. (ENVB)’s stock and average of those rates the stock at a “Moderate Buy” and assign it a score of 2.00. Out of those 1 Wall Street analysts, 1 recommended a “Buy” rating, while 0 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.
